TG Therapeutics, Inc. (NASDAQ:TGTX) Shares Sold by Barclays PLC

Barclays PLC reduced its stake in TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) by 8.5% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 317,563 shares of the biopharmaceutical company's stock after selling 29,494 shares during the period. Barclays PLC owned approximately 0.20% of TG Therapeutics worth $9,559,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the stock. Vanguard Group Inc. increased its holdings in TG Therapeutics by 1.4% during the 4th quarter. Vanguard Group Inc. now owns 15,596,480 shares of the biopharmaceutical company's stock worth $469,454,000 after purchasing an additional 209,190 shares during the period. Clearbridge Investments LLC purchased a new stake in shares of TG Therapeutics during the fourth quarter worth approximately $55,237,000. Charles Schwab Investment Management Inc. raised its holdings in TG Therapeutics by 7.2% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 1,269,513 shares of the biopharmaceutical company's stock valued at $38,212,000 after acquiring an additional 84,904 shares in the last quarter. Invesco Ltd. lifted its stake in TG Therapeutics by 1.2% in the fourth quarter. Invesco Ltd. now owns 929,743 shares of the biopharmaceutical company's stock worth $27,985,000 after acquiring an additional 10,989 shares during the last quarter. Finally, Bank of New York Mellon Corp grew its holdings in TG Therapeutics by 10.5% during the 4th quarter. Bank of New York Mellon Corp now owns 923,488 shares of the biopharmaceutical company's stock worth $27,797,000 after acquiring an additional 87,679 shares in the last quarter. 58.58% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of equities research analysts have recently weighed in on TGTX shares. HC Wainwright restated a "buy" rating and issued a $55.00 price objective on shares of TG Therapeutics in a report on Tuesday, March 4th. StockNews.com upgraded TG Therapeutics from a "sell" rating to a "hold" rating in a research note on Tuesday, March 4th. Two equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. According to data from MarketBeat, TG Therapeutics has an average rating of "Moderate Buy" and a consensus price target of $40.67.

TG Therapeutics Price Performance

Shares of TGTX opened at $37.99 on Wednesday. The company has a debt-to-equity ratio of 1.27, a current ratio of 4.59 and a quick ratio of 3.91. TG Therapeutics, Inc. has a 1-year low of $12.93 and a 1-year high of $43.32. The stock has a market cap of $5.97 billion, a PE ratio of -379.86 and a beta of 2.14. The firm has a fifty day moving average price of $36.61 and a 200 day moving average price of $32.13.

TG Therapeutics (NASDAQ:TGTX - Get Free Report) last announced its earnings results on Monday, March 3rd. The biopharmaceutical company reported $0.15 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.08 by $0.07. The firm had revenue of $108.19 million during the quarter, compared to analysts' expectations of $100.67 million. TG Therapeutics had a negative return on equity of 8.32% and a negative net margin of 5.42%. As a group, sell-side analysts anticipate that TG Therapeutics, Inc. will post 0.08 EPS for the current year.

TG Therapeutics Company Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.

Want to see what other hedge funds are holding TGTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.